Edition:
United States

MacroGenics Inc (MGNX.OQ)

MGNX.OQ on NASDAQ Stock Exchange Global Select Market

19.70USD
20 Nov 2017
Change (% chg)

$0.50 (+2.60%)
Prev Close
$19.20
Open
$19.15
Day's High
$19.93
Day's Low
$19.15
Volume
122,256
Avg. Vol
90,789
52-wk High
$28.44
52-wk Low
$14.36

Latest Key Developments (Source: Significant Developments)

Incyte and MacroGenics announce global collaboration and licensing agreement
Wednesday, 25 Oct 2017 06:45am EDT 

Oct 25 (Reuters) - Incyte Corp :Incyte and MacroGenics announce global collaboration and licensing agreement for Anti-PD-1 Monoclonal Antibody MGA012.MacroGenics inc - ‍Incyte gains exclusive, worldwide development and commercialization rights to MGA012 in all indications​.MacroGenics Inc - ‍upon closing, Incyte will pay MacroGenics an upfront payment of $150 million​.MacroGenics - ‍co is eligible to receive up to $420 million in potential development, regulatory milestones, up to $330 million in potential commercial milestones​.MacroGenics Inc - ‍MacroGenics retains right to manufacture a portion of both companies' global clinical and commercial supply needs of MGA012​.MacroGenics Inc - ‍MacroGenics intends to utilize its commercial-scale GMP facility, which is expected to be fully operational in 2018​.MacroGenics - ‍if MGA012 approved & commercialized, co will be eligible to get royalties, tiered from 15 percent to 24 percent, on future sales by Incyte​.  Full Article

Macrogenics announces termination of duvortuxizumab collaboration
Thursday, 31 Aug 2017 04:30pm EDT 

Aug 31 (Reuters) - Macrogenics Inc ::Macrogenics announces termination of duvortuxizumab collaboration and license agreement with Janssen.Macrogenics Inc - ‍enrollment of phase 1 dose-escalation study of this molecule is being discontinued​.Macrogenics Inc - ‍Janssen has indicated that it anticipates initiating a first-in-human study with molecule in 2018​.Macrogenics Inc - ‍Janssen reaffirmed its commitment to MGD015, also known as JNJ-9383, a second dart molecule licensed from Macrogenics​.Macrogenics Inc - ‍Janssen is terminating collaboration and license agreement with Macrogenics relating to duvortuxizumab, a CD19 X CD3 dart molecule​.Macrogenics Inc - ‍unlikely that co will continue development of duvortuxizumab, a CD19 X CD3 dart molecule "at this time​".  Full Article

Macrogenics Inc enters into sales agreement with Cowen and Company
Friday, 5 May 2017 08:55am EDT 

May 5 (Reuters) - Macrogenics Inc : :Macrogenics Inc says on May 3, 2017, company entered into sales agreement with Cowen and Company LLC .Macrogenics Inc says may sell shares of company's common stock, aggregate offering price of up to $75.0 million through Cowen and Co.  Full Article

Macrogenics announces registered direct offering of common stock
Thursday, 27 Apr 2017 07:00am EDT 

April 27 (Reuters) - Macrogenics Inc ::Macrogenics announces registered direct offering of common stock.Macrogenics - definitive agreement with institutional healthcare investor to purchase 1.1 million shares of stock at purchase price of $21.50/share.Macrogenics Inc- gross proceeds to macrogenics, before deducting estimated offering expenses, will be $23.65 million.Macrogenics Inc- shares were offered pursuant to company's shelf registration and offering is expected to close on or about May 2, 2017.  Full Article

Macrogenics provides announces 2016 financial results
Tuesday, 28 Feb 2017 04:01pm EST 

Macrogenics Inc : Macrogenics provides update on corporate progress and 2016 financial results .Macrogenics - expects its current cash, cash equivalents, anticipated funding under current collaborations, should fund co's operations through late 2018.  Full Article

First dosing of Pfizer DART candidate in phase 1 study triggers milestone payment to MacroGenics
Tuesday, 10 May 2016 07:30am EDT 

MacroGenics Inc : Commencement of phase 1 study triggers a $2 million milestone payment to MacroGenics under companies' October 2010 agreement. . Pfizer recently dosed a first patient in phase 1 clinical study of PF-06671008, which targets P-cadherin and CD3 .First dosing of Pfizer DART candidate in phase 1 study triggers milestone payment to MacroGenics.  Full Article

BRIEF-Macrogenics- increased number of directors that constitute board from eight to nine ​

* Macrogenics- increased number of directors that constitute board from eight to nine after approving appointment of Jay Siegel on Nov 13 - SEC filing ​ Source text: (http://bit.ly/2A2CHjE) Further company coverage: